BOLD Boundless Bio Inc.
510
$9.79
$0.44
(4.71%)
| Watchers | 510 |
| 52-Wk Low | $8.53 |
| 52-Wk High | $16.00 |
| Market Cap | $207.94M |
| Volume | 38,887.00 |
| 52-Wk High | $16.00 |
| 52-Wk Low | $8.53 |
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024Business Wire • about 5 hours ago
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene...
Share to Feed
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 PR Newswire VANCOUVER, BC, May 1, 2024 USA News Group Commentary...
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene...
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene...
Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable...